CGPHF (Grand Pharmaceutical Group) EPS (Basic): $0.05 (TTM As of Dec. 2025)


What is Grand Pharmaceutical Group EPS (Basic)?

Grand Pharmaceutical Group CGPHF 87 EPS (Basic) is $0.05 as of Dec. 2025. GuruFocus rates CGPHF with a GF Score™ of 87/100. The stock has 6 warning signs investors should review.

Grand Pharmaceutical Group's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was $0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.05.

Grand Pharmaceutical Group's EPS (Diluted) for the six months ended in Dec. 2025 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.05.

Grand Pharmaceutical Group's EPS without NRI for the six months ended in Dec. 2025 was $0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.05.

During the past 12 months, Grand Pharmaceutical Group's average EPS without NRIGrowth Rate was -23.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was -12.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -2.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 19.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Grand Pharmaceutical Group's highest 3-Year average EPS without NRI Growth Rate was 56.30% per year. The lowest was -12.20% per year. And the median was 29.80% per year.

Grand Pharmaceutical Group  (OTCPK:CGPHF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Grand Pharmaceutical Group EPS (Basic) Related Terms

Grand Pharmaceutical Group EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Grand Pharmaceutical Group's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grand Pharmaceutical Group EPS (Basic) Chart

Grand Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.08 0.07 0.09 0.05

Grand Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.06 0.03 0.04 0.00

Grand Pharmaceutical Group EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Grand Pharmaceutical Group's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(159.479-0)/3501.810
=0.05

Grand Pharmaceutical Group's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(9.235-0)/3501.810
=0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $0.05 mean?
Grand Pharmaceutical Group (CGPHF) has a EPS (Basic) of $0.05 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Grand Pharmaceutical Group and its competitors.
Is Grand Pharmaceutical Group's EPS (Basic) too high?
Grand Pharmaceutical Group's current EPS (Basic) is $0.05. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's EPS (Basic) compare to ZTS?
Grand Pharmaceutical Group's EPS (Basic) of $0.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Grand Pharmaceutical Group and its competitors. Grand Pharmaceutical Group's current EPS (Basic) is $0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current EPS (Basic) of $0.05. The current EPS (Basic) is $0.05. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current EPS (Basic) is $0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grand Pharmaceutical Group Business Description

Other Exchanges 00512:Hong KongMX6A:Germany
Address 99 Queen\'s Road Central, Units 3302, 33rd Floor, The Center, Hong Kong, HKG
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.